Scorpius Holdings Appoints New VP of Business Development Shari Udoff-McDonald
May 07 2024 - 8:30AM
Scorpius Holdings, Inc. (NYSE American: SCPX)
(“Scorpius” or the “Company”), an integrated
contract development and manufacturing organization (CDMO), today
announced the appointment of Shari Udoff-McDonald as VP of Business
Development. She brings more than 25 years of experience in
biopharma business development and management.
Prior to joining Scorpius, Ms. Udoff-McDonald spent 17 years at
BioReliance Corporation, part of MilliporeSigma. She was most
recently Head of Commercial, North America, East with interim
oversight of half of the European market. Her role included
commercial oversight of biologics, vaccines, cell and gene
therapies, ADCs, and mRNA GMP testing services for sponsors and
CDMOs.
Joe Payne, Scorpius’ President and COO, said, “Shari has the
unique combination of experience in the field, at the
account-level, and in leadership roles. This wide breadth of
business development experience will help Scorpius continue to grow
its customer base. I’m confident that Shari will have an immediate,
positive impact on our current and future clients.”
Ms. Udoff-McDonald will oversee the business development,
marketing, and proposals teams, which are addressing the strong
demand for flexible mammalian and microbial biomanufacturing
services. Scorpius’ facility in San Antonio, Texas, has available
capacity for mammalian and microbial programs, which are supported
by on-site process and analytical development services.
“I’m thrilled to join Scorpius BioManufacturing at this key
growth stage,” said Ms. Udoff-McDonald. “Scorpius is committed to
being a transparent, flexible, and responsive CDMO partner. I am
impressed by their technical and scientific capabilities and am
even more impressed by the passion and enthusiasm displayed by the
team. I look forward to working with current and future clients to
bring their large molecule drugs to market.”
Ms. Udoff-McDonald and the Scorpius business
development team will be at the BIO International Convention in San
Diego on June 3-6. To schedule a meeting, visit
https://www.scorpiusbiologics.com/contact-us.
About Scorpius Holdings
Scorpius BioManufacturing Inc. is a wholly owned subsidiary of
Scorpius Holdings Inc., an integrated contract development and
manufacturing organization (CDMO) focused on rapidly advancing
biologic and cell therapy programs to the clinic and beyond.
Scorpius offers a broad array of analytical testing, process
development, and manufacturing services to pharmaceutical and
biotech companies at its state-of-the-art facilities in San
Antonio, TX. With an experienced team and new, purpose-built U.S.
facilities, Scorpius is dedicated to transparent collaboration and
flexible, high-quality biologics biomanufacturing. For more
information, please visit www.scorpiusbiologics.com.
Forward-Looking Statement
This release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. In
some cases, forward-looking statements can be identified by
terminology such as "may," "should," "potential," "continue,"
"expects," "anticipates," "intends," "plans," "believes,"
"estimates," and similar expressions, and include statements such
as contributions to be made by Shari Udoff-McDonald including her
business development experience helping Scorpius continuing to grow
its customer base and working with current and future clients to
bring their large molecule drugs to market. Important factors that
could cause actual results to differ materially from current
expectations include, among others, the ability of Shari
Udoff-McDonald to make contributions to Scorpius, the Company’s
ability to regain compliance with the NYSE American continued
listing standards, expand its large molecule biomanufacturing CDMO
services and continue to grow revenue; the Company’s financing
needs, its cash balance being sufficient to sustain operations and
its ability to raise capital when needed, the Company’s ability to
leverage fixed costs and achieve long-term profitability; the
Company’s ability to obtain regulatory approvals or to comply with
ongoing regulatory requirements, regulatory limitations relating to
the Company’s ability to successfully promote its services and
compete as a pure- play CDMO, and other factors described in the
Company’s most recent annual report on Form 10-K for the year ended
December 31, 2023, subsequent quarterly reports on Form 10-Qs and
any other filings the Company makes with the SEC. The information
in this presentation is provided only as of the date presented, and
the Company undertakes no obligation to update any forward-looking
statements contained in this presentation on account of new
information, future events, or otherwise, except as required by
law.
Media & Investor Relations ContactDavid
Waldman+1 919 289 4017ir@scorpiusbiologics.com
Scorpius (AMEX:SCPX)
Historical Stock Chart
From Apr 2024 to May 2024
Scorpius (AMEX:SCPX)
Historical Stock Chart
From May 2023 to May 2024